Vyne Therapeutics Inc. VYNE
We take great care to ensure that the data presented and summarized in this overview for VYNE Therapeutics Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in VYNE
Top Purchases
Top Sells
About VYNE
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Insider Transactions at VYNE
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 30
2024
|
Mutya Harsch CHIEF LEGAL OFFICER AND GC |
SELL
Payment of exercise price or tax liability
|
Direct |
105
-0.07%
|
$105
$1.88 P/Share
|
|
Sep 30
2024
|
David Domzalski PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
685
-0.14%
|
$685
$1.88 P/Share
|
|
Sep 30
2024
|
Iain Stuart CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
109
-0.08%
|
$109
$1.88 P/Share
|
|
Sep 30
2024
|
Tyler Zeronda CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
84
-0.06%
|
$84
$1.88 P/Share
|
|
Jul 01
2024
|
David Domzalski PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
935
-0.19%
|
$935
$1.92 P/Share
|
|
Jul 01
2024
|
Mutya Harsch CHIEF LEGAL OFFICER AND GC |
SELL
Payment of exercise price or tax liability
|
Direct |
143
-0.1%
|
$143
$1.92 P/Share
|
|
Jul 01
2024
|
Iain Stuart CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
138
-0.1%
|
$138
$1.92 P/Share
|
|
Jul 01
2024
|
Tyler Zeronda CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
92
-0.07%
|
$92
$1.92 P/Share
|
|
May 31
2024
|
David Domzalski PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
4,429
+0.88%
|
$8,858
$2.16 P/Share
|
|
Apr 01
2024
|
Iain Stuart CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
157
-0.12%
|
$471
$3.08 P/Share
|
|
Apr 01
2024
|
Tyler Zeronda CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
94
-0.07%
|
$282
$3.08 P/Share
|
|
Apr 01
2024
|
David Domzalski PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,004
-0.2%
|
$3,012
$3.08 P/Share
|
|
Apr 01
2024
|
Mutya Harsch CHIEF LEGAL OFFICER AND GC |
SELL
Payment of exercise price or tax liability
|
Direct |
161
-0.11%
|
$483
$3.08 P/Share
|
|
Jan 02
2024
|
Mutya Harsch CHIEF LEGAL OFFICER AND GC |
SELL
Payment of exercise price or tax liability
|
Direct |
161
-0.11%
|
$322
$2.28 P/Share
|
|
Jan 02
2024
|
Iain Stuart CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
157
-0.12%
|
$314
$2.28 P/Share
|
|
Jan 02
2024
|
Tyler Zeronda CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
93
-0.07%
|
$186
$2.28 P/Share
|
|
Jan 02
2024
|
David Domzalski PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,004
-0.2%
|
$2,008
$2.28 P/Share
|
|
Jan 01
2024
|
Mutya Harsch CHIEF LEGAL OFFICER AND GC |
BUY
Grant, award, or other acquisition
|
Direct |
62,500
+29.47%
|
-
|
|
Jan 01
2024
|
Iain Stuart CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
62,500
+31.8%
|
-
|
|
Jan 01
2024
|
Tyler Zeronda CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
62,500
+32.15%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 832K shares |
|---|
| Payment of exercise price or tax liability | 5.12K shares |
|---|